Lynparza granted FDA Priority Review for OlympiA
30 November 2021 07:00 GMT Lynparza granted Priority Review in the US forBRCA-mutated HER2-negative high-risk early breast cancer First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Lynparza is being jointly developed and